Aditi Shendre1, Todd M Brown2, Nianjun Liu3, Charles E Hill4, T Mark Beasley3, Deborah A Nickerson5, Nita A Limdi6. 1. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama. 2. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 3. Biostatistics, Section on Statistical Genetics, University of Alabama at Birmingham, Birmingham, Alabama. 4. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia. 5. Genome Sciences, School of Medicine, University of Washington, Seattle, Washington. 6. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama.
Abstract
OBJECTIVE: The p.V433M in cytochrome P450 4F2 (rs2108622, CYP4F2*3) is associated with a higher warfarin dose and lower risk of hemorrhage among European Americans. We evaluate the influence of CYP4F2*3 on warfarin dose, time to target international normalized ratio (INR), and stable dose, proportion of time spent in target range (PTTR), as well as the risk of overanticoagulation and hemorrhage among European and African Americans. DESIGN: CYP4F2*3 was genotyped in 1238 patients initiated on warfarin in a prospective inception cohort. Multivariable linear regression was used to assess warfarin dose and PTTR; proportional hazards analysis was performed to evaluate time to target INR and stable dose, overanticoagulation, and hemorrhage. SETTING: Two outpatient anticoagulation clinics. PARTICIPANTS: A total of 1238 anticoagulated patients. OUTCOMES: Warfarin dose (mg/day), time to target INR and stable dose, PTTR, overanticoagulation (INR more than 4), and major hemorrhage. RESULTS: Minor allele frequency for the CYP4F2*3 variant was 30.3% among European Americans and 8.4% among African Americans. CYP4F2*3 was associated with higher dose among European Americans but not African Americans. Compared to CYP4F2*1/*1, *1/*3 was associated with a statistically nonsignificant increase in dose (4.5%, p=0.22) and *3/*3 was associated with a statistically significant increase in dose (13.2%, p=0.02). CYP4F2 genotype did not influence time to target INR, time to stable dose, or PTTR in either race group. CYP4F2*3/*3 was associated with a 31% lower risk of over anticoagulation (p=0.06). Incidence of hemorrhage was lower among participants with CYP4F2 *3/*3 compared with *1/*3 or *1/*1 (incidence rate ratio = 0.45, 95% confidence interval 0.14-1.11, p=0.09). After controlling for covariates, CYP4F2 *3/*3 was associated with a 52% lower risk of hemorrhage, although this was not statistically significant (p=0.24). CONCLUSION: Possession of CYP4F2*3 variant influences warfarin dose among European Americans but not African Americans. The CYP4F2-dose, CYP4F2-overanticoagulation, and CYP4F2-hemorrhage association follows a recessive pattern with possession of CYP4F2*3/*3 genotype likely demonstrating a protective effect. These findings need further confirmation.
OBJECTIVE: The p.V433M in cytochrome P450 4F2 (rs2108622, CYP4F2*3) is associated with a higher warfarin dose and lower risk of hemorrhage among European Americans. We evaluate the influence of CYP4F2*3 on warfarin dose, time to target international normalized ratio (INR), and stable dose, proportion of time spent in target range (PTTR), as well as the risk of overanticoagulation and hemorrhage among European and African Americans. DESIGN:CYP4F2*3 was genotyped in 1238 patients initiated on warfarin in a prospective inception cohort. Multivariable linear regression was used to assess warfarin dose and PTTR; proportional hazards analysis was performed to evaluate time to target INR and stable dose, overanticoagulation, and hemorrhage. SETTING: Two outpatient anticoagulation clinics. PARTICIPANTS: A total of 1238 anticoagulated patients. OUTCOMES: Warfarin dose (mg/day), time to target INR and stable dose, PTTR, overanticoagulation (INR more than 4), and major hemorrhage. RESULTS: Minor allele frequency for the CYP4F2*3 variant was 30.3% among European Americans and 8.4% among African Americans. CYP4F2*3 was associated with higher dose among European Americans but not African Americans. Compared to CYP4F2*1/*1, *1/*3 was associated with a statistically nonsignificant increase in dose (4.5%, p=0.22) and *3/*3 was associated with a statistically significant increase in dose (13.2%, p=0.02). CYP4F2 genotype did not influence time to target INR, time to stable dose, or PTTR in either race group. CYP4F2*3/*3 was associated with a 31% lower risk of over anticoagulation (p=0.06). Incidence of hemorrhage was lower among participants with CYP4F2 *3/*3 compared with *1/*3 or *1/*1 (incidence rate ratio = 0.45, 95% confidence interval 0.14-1.11, p=0.09). After controlling for covariates, CYP4F2 *3/*3 was associated with a 52% lower risk of hemorrhage, although this was not statistically significant (p=0.24). CONCLUSION: Possession of CYP4F2*3 variant influences warfarin dose among European Americans but not African Americans. The CYP4F2-dose, CYP4F2-overanticoagulation, and CYP4F2-hemorrhage association follows a recessive pattern with possession of CYP4F2*3/*3 genotype likely demonstrating a protective effect. These findings need further confirmation.
Authors: Katarzyna Drozda; Yana Labinov; Ruixuan Jiang; Margaret R Thomas; Shan S Wong; Shitalben Patel; Edith A Nutescu; Larisa H Cavallari Journal: Am J Pharm Educ Date: 2013-10-14 Impact factor: 2.047
Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: K Nakamura; K Obayashi; T Araki; T Aomori; Y Fujita; Y Okada; M Kurabayashi; A Hasegawa; S Ohmori; T Nakamura; K Yamamoto Journal: J Clin Pharm Ther Date: 2011-12-16 Impact factor: 2.512
Authors: Adam Bress; Shitalben R Patel; Minoli A Perera; Richard T Campbell; Rick A Kittles; Larisa H Cavallari Journal: Pharmacogenomics Date: 2012-12 Impact factor: 2.533
Authors: E Danese; M Montagnana; J A Johnson; A E Rettie; C F Zambon; S A Lubitz; G Suarez-Kurtz; L H Cavallari; L Zhao; M Huang; Y Nakamura; T Mushiroda; M K Kringen; P Borgiani; C Ciccacci; N T Au; T Langaee; V Siguret; M A Loriot; H Sagreiya; R B Altman; M H A Shahin; S A Scott; S I Khalifa; B Chowbay; I M Suriapranata; M Teichert; B H Stricker; M Taljaard; M R Botton; J E Zhang; M Pirmohamed; X Zhang; J F Carlquist; B D Horne; M T M Lee; V Pengo; G C Guidi; P Minuz; C Fava Journal: Clin Pharmacol Ther Date: 2012-11-07 Impact factor: 6.875
Authors: Munir Pirmohamed; Girvan Burnside; Niclas Eriksson; Andrea L Jorgensen; Cheng Hock Toh; Toby Nicholson; Patrick Kesteven; Christina Christersson; Bengt Wahlström; Christina Stafberg; J Eunice Zhang; Julian B Leathart; Hugo Kohnke; Anke H Maitland-van der Zee; Paula R Williamson; Ann K Daly; Peter Avery; Farhad Kamali; Mia Wadelius Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Minoli A Perera; Larisa H Cavallari; Nita A Limdi; Eric R Gamazon; Anuar Konkashbaev; Roxana Daneshjou; Anna Pluzhnikov; Dana C Crawford; Jelai Wang; Nianjun Liu; Nicholas Tatonetti; Stephane Bourgeois; Harumi Takahashi; Yukiko Bradford; Benjamin M Burkley; Robert J Desnick; Jonathan L Halperin; Sherief I Khalifa; Taimour Y Langaee; Steven A Lubitz; Edith A Nutescu; Matthew Oetjens; Mohamed H Shahin; Shitalben R Patel; Hersh Sagreiya; Matthew Tector; Karen E Weck; Mark J Rieder; Stuart A Scott; Alan H B Wu; James K Burmester; Mia Wadelius; Panos Deloukas; Michael J Wagner; Taisei Mushiroda; Michiaki Kubo; Dan M Roden; Nancy J Cox; Russ B Altman; Teri E Klein; Yusuke Nakamura; Julie A Johnson Journal: Lancet Date: 2013-06-05 Impact factor: 79.321
Authors: Elisa Danese; Sara Raimondi; Martina Montagnana; Angela Tagetti; Taimour Langaee; Paola Borgiani; Cinzia Ciccacci; Antonio J Carcas; Alberto M Borobia; Hoi Y Tong; Cristina Dávila-Fajardo; Mariana Rodrigues Botton; Stephane Bourgeois; Panos Deloukas; Michael D Caldwell; Jim K Burmester; Richard L Berg; Larisa H Cavallari; Katarzyna Drozda; Min Huang; Li-Zi Zhao; Han-Jing Cen; Rocio Gonzalez-Conejero; Vanessa Roldan; Yusuke Nakamura; Taisei Mushiroda; Inna Y Gong; Richard B Kim; Keita Hirai; Kunihiko Itoh; Carlos Isaza; Leonardo Beltrán; Enrique Jiménez-Varo; Marisa Cañadas-Garre; Alice Giontella; Marianne K Kringen; Kari Bente Foss Haug; Hye Sun Gwak; Kyung Eun Lee; Pietro Minuz; Ming Ta Michael Lee; Steven A Lubitz; Stuart Scott; Cristina Mazzaccara; Lucia Sacchetti; Ece Genç; Mahmut Özer; Anil Pathare; Rajagopal Krishnamoorthy; Andras Paldi; Virginie Siguret; Marie-Anne Loriot; Vijay Kumar Kutala; Guilherme Suarez-Kurtz; Jamila Perini; Josh C Denny; Andrea H Ramirez; Balraj Mittal; Saurabh Singh Rathore; Hersh Sagreiya; Russ Altman; Mohamed Hossam A Shahin; Sherief I Khalifa; Nita A Limdi; Charles Rivers; Aditi Shendre; Chrisly Dillon; Ivet M Suriapranata; Hong-Hao Zhou; Sheng-Lan Tan; Vacis Tatarunas; Vaiva Lesauskaite; Yumao Zhang; Anke H Maitland-van der Zee; Talitha I Verhoef; Anthonius de Boer; Monica Taljaard; Carlo Federico Zambon; Vittorio Pengo; Jieying Eunice Zhang; Munir Pirmohamed; Julie A Johnson; Cristiano Fava Journal: Clin Pharmacol Ther Date: 2019-02-17 Impact factor: 6.875
Authors: Salina P Waddy; Allen J Solomon; Adan Z Becerra; Julia B Ward; Kevin E Chan; Chyng-Wen Fwu; Jenna M Norton; Paul W Eggers; Kevin C Abbott; Paul L Kimmel Journal: J Am Soc Nephrol Date: 2020-02-20 Impact factor: 10.121
Authors: Nita A Limdi; Todd M Brown; Aditi Shendre; Nianjun Liu; Charles E Hill; Timothy M Beasley Journal: Pharmacogenet Genomics Date: 2017-10 Impact factor: 2.089
Authors: Megan V Yanik; Marguerite R Irvin; T Mark Beasley; Pamala A Jacobson; Bruce A Julian; Nita A Limdi Journal: Pharmacotherapy Date: 2017-11-02 Impact factor: 4.705
Authors: W Hernandez; E R Gamazon; K Aquino-Michaels; E Smithberger; T J O'Brien; A F Harralson; M Tuck; A Barbour; L H Cavallari; M A Perera Journal: J Thromb Haemost Date: 2017-03-25 Impact factor: 5.824
Authors: Nianjun Liu; Marguerite R Irvin; Degui Zhi; Amit Patki; T Mark Beasley; Deborah A Nickerson; Charles E Hill; Jinbo Chen; Stephen E Kimmel; Nita A Limdi Journal: Pharmacogenomics Date: 2017-07-07 Impact factor: 2.533